Cytimm Therapeutics
Wednesday, June 05, 2024
Company Presentation
![Oncology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Oncology_MTC.png)
Company Presentation Theater 1
Cytimm Therapeutics is a clinical-stage biopharmaceutical company located in San Diego. We are focusing on the development of innovative IL-2 based therapies with First-In-Class potential for cancer, neurodegenerative and autoimmune diseases. Cytimm uses innovative technologies to decouple the two opposite functions of IL-2 and developed two proprietary IL-2 based drugs, CTM103 and CTM201, each targets a spectrum of diseases: CTM103 targets solid tumors including Lung Cancer, Melanoma, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Colon Cancer, Bladder Cancer; CTM201 targets Systemic lupus erythematosus (SLE), Psoriasis, Ulcerative Colitis (UC), Atopic Dermatitis, Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson's disease. These two “pipeline-in-a-product” assets have the potential to make tremendous impacts, both socially and commercially.
![Cytimm Therapeutics](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1820572-1-JPG.png)
Company Website:
http://www.cytimm.com
Lead Product in Development:
CTM103
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
San Diego
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Haining Huang
Development Phase of Primary Product
Phase I
Primary Speaker